Address: 15 rue des Vanesses, Zone Paris Nord II, 93420 Villepinte, France
Tel: 33 (0) 1 45 91 50 00
Website: http://www.guerbet.com/
An international pharmaceutical group specialized in medical imaging, Guerbet is directly present in most of the world’s markets. From Research & Development to distribution, Guerbet exerts full control over the entire range of pharma processes. Headquartered outside Paris, the company distributes its products worldwide via international affiliates. Guerbet also has a research center and 9 different manufacturing plants around the world, as well as a network of logistics centers on four continents.
Guerbet’s Alessandro Bocci – General Manager Italy & Iberia – describes the nearly 100-year-old company’s firm position in the field of contrast media for radiology and its plans for developing…
In an exclusive interview, Yves L’Epine, president of G5 Santé and CEO of Guerbet, offers his insider take on the business climate in French healthcare and the potential for France…
Roberto Godoy, GM of Guerbet Brazil and marketing director of Guerbet Latin America, a leading French-based contrast media company present in Brazil for the past 40 years, explains his role…
Lionel Collet, president of France’s Haute Autorité de Santé (HAS), explains the role of the independent public authority, which extends beyond health technology assessment (HTA) to clinical practice guidelines and…
FACOPHAR Santé is the French association for actors operating in the natural and herbal remedies field. In conversation with PharmaBoardroom, long-term president Jacques Vernin explains how the organisation promotes French…
The biggest stories from French healthcare and pharma, including AstraZeneca’s acquisition of Amolyt Pharma; protests over Sanofi layoffs; Pierre Fabre’s purchase of Kinnate Biopharma’s experimental pan-RAF inhibitor, and French biotech…
As president of the French League Against Cancer, Dr Daniel Nizri highlights the organization’s 106-year legacy of fighting cancer through research funding, health promotion, patient support, and advocacy. He discusses…
After offloading its consumer healthcare division in 2022 and in view of the gradual erosion of its top seller, Somatuline, Ipsen opted to aggressively seek external assets to enrich its…
France is the third most significant clinical research destination in Europe, participating in 50 percent of the trials initiated across the continent. While favourable government policies and unique strengths such…
Hubert Mechin, president of AFCROs, the association that groups clinical research organisations in France, details the organisation’s efforts to help its members stay abreast of changes in the European regulatory…
With revenues projected to reach USD 27.01 billion in 2024, France’s pharma market is ranked fifth globally. Home to a number of well-established local pharma players and a sought-after destination…
Just five months after taking office, Aurélien Rousseau resigned from his role as health minister in protest against France’s recently adopted immigration law. Interim replacement Agnès Firmin Le Bodo, the…
France’s life sciences industry is falling behind its European neighbours, its growth deeply hampered, the French life sciences think tank G5 Santé claims, by abusive paybacks. While the government has…
The latest news from French healthcare and pharma, including an update on the hospital crisis; MaaT Pharma and Skyepharma’s new cGMP microbiome facility; Sanofi’s offloading of central nervous system drugs…
In the French government’s recent cabinet reshuffle, prime minister Elisabeth Borne’s former chief of staff, Aurélien Rousseau was appointed as the new minister of health. Rousseau, having piloted the Île-de-France…
See our Cookie Privacy Policy Here
